Chemo may be preferred option for some with advanced prostate cancer
the ONA take:
According to the results of a small clinical trial published online in JAMA Oncology, researchers from Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute in Baltimore, Maryland, have found that men with advanced prostate cancer who possess the androgen receptor splice variant-7 (AR-V7) respond just as well to chemotherapy as those who lack AR-V7.
The AR-V7 gene variant has been shown to confer resistance to enzalutamide or abiraterone, two hormonal drugs used to treated castration-resistant prostate cancer; however, the study found that patients with the variant respond similarly to docetaxel or cabazitaxel compared with those without the gene variant.
"Our study shows that men who have the AR-V7 gene variant and usually don't respond to either abiraterone or enzalutamide, are not at a disadvantage when given chemotherapy drugs," says Emmanuel Antonarakis, M.D., an oncologist at the Kimmel Cancer Center.
The researchers are currently working to develop and validate a test to detect AR-V7 in patients with advanced prostate cancer to better inform treatment decisions.
Men with advanced prostate cancer who possess AR-V7 respond just as well to chemotherapy as those who lack AR-V7.
Sign Up for Free e-newsletters
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Cervical Cancer Outcomes Comparable With Adjuvant Chemotherapy, Chemoradiotherapy
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|